Nicergoline
From Wikipedia, the free encyclopedia
Nicergoline
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | |
ATC code | C04 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C24H26BrN3O3 |
Mol. mass | 484.386 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Nicergoline is an ergoloid mesylate derivative used to treat senile dementia and other disorders with vascular origins. It has been found to increase mental agility and enhance clarity and perception. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs.
It is used for vascular disorders such as cerebral thrombosis and atherosclerosis, arterial blockages in the limbs, Raynaud's disease, vascular migraines, and retinopathy.
Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people. [1]
It is marketed under the trade name Sermion.
Contents |
[edit] Pharmacological action
Nicergoline has alpha-adrenolytic action which activates the brain's metabolism and improves arterial flow, lowers vascular resistance and improves the use of glucose and oxygen. Furthermore, it is known that Nicergoline inhibits platelet aggregation. Studies have shown that Nicergoline also increases nerve growth factor in the aged brain.
[edit] Use and Dosage
Nicerogline is used in the following cases:
- Acute and chronic cerebral metabolic-vascular disorders (cerebral arteriosclerosis, thrombosis and cerebral embolism, transitory cerebral ischaemia). Acute and chronic peripheral metabolic-vascular disorders (organic and functional arteriopathies of the limbs), Raynaud’s disease and other syndromes caused by altered peripheral irrigation.
- Migraines of vascular origin
- Coadjutant therapy in clinical situations accompanied by platelet hyper-aggregability, arterial tension.
- Corio-retinal vascular disorders: , diabetic retinopathy, macular degeneration and retinal angiosclerosis
- Oto-vestibular problems of a vascular nature: dizziness, auditory hallucinations, hypoacusis.
Dosages for known conditions are usually administered at 5-10mg three times a day, however anti-aging preventative purposes may want to consider 5mg once or twice a day more adequate. [2]
[edit] Contraindications and cautions
Persons suffering from acute bleeding, myocardial infarction (heart conditions), hypertension, bradycardia or using alpha or beta receptor agonists should consult with their physician before use. Although toxicology studies have not shown nicergoline to have any teratogenic effect, the use of this medicine during pregnancy should be limited to those cases where it is absolutely necessary.
[edit] Side Effects
Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with this medicine. Because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. Nicergoline can cause side effects they are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness. At high dosages bradycardia, increased appetite, agitation, diarrhea and perspiration have been known to present themselves. There was a single case of Acute Interstitial Nephritis. [3]
[edit] Interactions
Nicergoline is known to enhance the cardiac depressive effects of propranolol (Inderal®) - caution is advised. At high dosages, it is advisable to seek one’s physician's guidance if combining with potent vasodilators such as Bromocriptine, Ginko Biloba, Hydergine, Picamilone, Vinpocetine or Xanthinol Nicotinate.
[edit] References
[edit] Notes
- ^ Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD003159. DOI: 10.1002/14651858.CD003159. Retrieved on 2008-05-27.
- ^ Nicergoline drug insert, Pharmacia & Upjohn, October 2000
- ^ Nephron Journal , Vol.92 , October 2002 , Nephron 2002;92:676-679 (DOI: 10.1159/000064096)
[edit] External Links
National Electronic Library for Medicines Nicergoline for dementia and other age associated forms of cognitive impairment.
|